Federal grants to Altay Therapeutics, Inc
Altay Therapeutics, Inc in San Carlos, California received $1.6 million in federal grants from fiscal 2021 to 2025, across 5 awards. Its largest program was Cardiovascular Diseases Research, with $599,067. In fiscal 2025 more was taken back from its awards than added, a net -$753.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$1.6 million
- Awards5
- Awarded in FY 2025-$753
- Largest award$399,869
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 0 | $0 |
| FY 2022 | 3 | $998,528 |
| FY 2023 | 1 | $275,000 |
| FY 2024 | 1 | $299,999 |
| FY 2025 | 0 | -$753 |
Programs that fund Altay Therapeutics, Inc
| Program | Awards | Amount |
|---|---|---|
| Cardiovascular Diseases Research | 2 | $599,067 |
| Cancer Treatment Research | 1 | $399,869 |
| National Center for Advancing Translational Sciences | 1 | $298,838 |
| Technology, Innovation, and Partnerships | 1 | $275,000 |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 4 | $1.3 million |
| National Science Foundation | 1 | $275,000 |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Novel STAT3 inhibitor for overcoming chemoresistant ovarian cancer . - abstract/summary epithelial ovarian cancer (OC) is the fifth leading cause of death in women and the most lethal gynecological malignancy in the united states. Oc is mostly diagnosed at an advanced stage. Patients undergo debulki | Cancer Treatment Research | September 19, 2022 | $399,869 |
| The development of a STAT3 inhibitor for lung scleroderma - abstract/summary systemic sclerosis (SSC) is an autoimmune disorder driven by inflammation, fibrosis, and microvascular disease that effects 75,000 americans and over 2.5M people word wide. The common histopathological features of ssc are e | Cardiovascular Diseases Research | May 10, 2024 | $299,999 |
| The development of a transcriptional inhibitor for lung fibrosis. - abstract/summary idiopathic pulmonary fibrosis (IPF) affects 100,000 people in the us with total incidences to increase 5% every year. The 5-YEAR survival rate of patients suffering from ipf is between 20-40%. Esbriet and nintedanib | Cardiovascular Diseases Research | May 19, 2022 | $299,068 |
| Development of a direct DUX4 inhibitor for facioscapulohumeral muscular dystrophy (FSHD) - abstract/summary facioscapulohumeral dystrophy (FSHD) is the third most common form of muscular dystrophy affecting over 30,000 americans. Fshd is a progressive disease where patients initially lose muscle cel | National Center for Advancing Translational Sciences | August 29, 2022 | $298,838 |
| Sbir phase i: targeting the root cause of ewing?s sarcoma -the broader impact of this small business innovation research (SBIR) phase i project is to treat pediatric patients affected with ewing?s sarcoma by targeting the root cause of the disease. Using a novel approach, new therapeutics will be de | Technology, Innovation, and Partnerships | September 14, 2023 | $275,000 |
Questions people ask
How much federal grant money does Altay Therapeutics, Inc get?
$1.6 million in 5 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Altay Therapeutics, Inc the most?
The Department of Health and Human Services, with $1.3 million in 4 awards. The National Science Foundation follow.
What is Altay Therapeutics, Inc's largest federal grant?
$399,869 under Cancer Treatment Research, with its first action in the period on September 19, 2022. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Altay Therapeutics, Inc?
Its largest are Cardiovascular Diseases Research, Cancer Treatment Research and National Center for Advancing Translational Sciences.
Other grant recipients in San Carlos
- Peninsula Corridor Joint Powers Board
- San Mateo County Transit District
- Swift Solar Inc
- Ihp Therapeutics Inc
- Village Enterprise Fund, Inc.
- Dorian Therapeutics Inc
- Siolta Therapeutics Inc
- Onc.ai, Inc.
Largest federal grant recipients in California · Federal grants in California